InvestorsHub Logo
Followers 8
Posts 288
Boards Moderated 0
Alias Born 11/12/2018

Re: BaaBaa45 post# 178064

Wednesday, 02/27/2019 6:38:59 AM

Wednesday, February 27, 2019 6:38:59 AM

Post# of 424701
"Try to think more about peak sales world wide, work out a reasonable multiple of that and have regard to the opportunity Vascepa presents worldwide because that's what seasoned BP executives will be doing with models and comparables to hand."

Worldwide sales and the drug has yet to even be approved for the R-IT indication the U.S? I'll leave the world wide peak sales stuff in the realm of hopes/dreams/fantasy for the time being until the FDA actually approves the R-IT sNDA first. You can do what you will.

"But then again if you want to pedal a negative agenda for your own trading ends go right ahead I think this MB sees right through you."

I think the vast majority of this board own the stock and have an obvious bias towards a higher stock price. They only hear what they want to hear and disregard all the rest. Cognitive bias. Look it up.

"Negative agenda" for my own trading purposes? As previously stated, I do not short stocks. IMO shorting stocks is a mugs game. I buy stock when I consider it cheap/good value and I sell it when I consider it expensive/over-valued. I sold all my Amarin holdings very recently because I consider the stock to be now overvalued. I am am fully aware of its future upside potential and will be watching it closely looking to re-enter at a price that I deem to be cheap/good value. In the meantime I will use the cash from the proceeds of my sale to invest elsewhere in companies that I believe to be cheap/good value. I have identified several that offer far greater upside potential IMO than Amarin does between now and the FDA's sNDA decision.

Is that ok with you?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News